ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1127

Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study

Ping-Han Tsai and Chang-Fu Kuo, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cerebrovascular disease, gout and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To determine whether the Taiwanese patients with gout have a higher risk of stroke.

Methods: Using the National Health Insurance database, we identified a cohort of new-onset gout patients in Taiwan between 2000 and 2005, follow up till 2015. The gout cohort was frequency-matched according to birth year and gender with patients without gout (control cohort). Cumulative probability and multivariable hazard ratio (HR) adjusted by age, sex, Charlson comorbidity index and co-medication was performed to evaluated the risk of stroke, including ischemic and hemorrhage stroke.

Results: In this study, we identified 646,983 incident patients with 1:1 matched of control group without gout. The incidence (100 person-years) of ischemic stroke and hemorrhagic stroke were both higher in gout group [7.26 (95% CI, 7.19-7.33); 2.47 (95% CI, 2.42 – 2.51) respectively] than control group [5.95 (95% CI, 5.88 – 6.01); 2.04 (95% CI, 2-2.07), respectively]. Both risk of ischemic stroke and hemorrhage stroke were higher in gout group (HR 1.15, 95% CI 1.14-1.17; HR 1.17, 95% CI 1.14-1.20, respectively) (Table).

Conclusion: Patients in Taiwan with gout have a higher risk of stroke, including ischemic stroke and hemorrhagic stroke. The incidence of ischemic stroke was three-fold than hemorrhagic stroke in gout patient.

Table Clinical characteristics of patients and Hazard ratios for incidence of stroke.

Gout (n= 646,983)

No Gout (n= 646,983)

P Value

Sex, No. (%)

Male

473362(73.16)

473362(73.16)

1.0000

Female

173611(26.83)

173611(26.83)

Age, mean (SD), y

49.63 (17.18)

49.62 (17.18)

0.9476

Hypertension

165148(25.53)

107091(16.55)

<.0001

Ischemic stroke

Incidence/100 person-years(95%CI)

7.26(7.19-7.33)

5.95(5.88-6.01)

No. of case, (%)

39812(6.15)

32619(5.04)

Age and sex adjusted Hazard Ratio(95%CI)

1.26(1.24-1.28)*

1.0

Multivariable Hazard Ratio﹟ (95% CI)

1.16(1.14-1.18)*

1.0

Multivariable Hazard Ratio† (95% CI)

1.15(1.14-1.17)*

1.0

Hemorrhagic stroke

Incidence/100 person-years(95%CI)

2.47(2.42-2.51)

2.04(2-2.07)

No. of case, (%)

13703(2.12)

11289(1.74)

Age and sex adjusted Hazard Ratio(95%CI)

1.23(1.20-1.26)*

1.0

Multivariable Hazard Ratio﹟ (95% CI)

1.16(1.13-1.19)*

1.0

Multivariable Hazard Ratio† (95% CI)

1.17(1.14-1.20)*

1.0

﹟adjusted for age, sex and charlson comorbidity index (myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, Renal failure, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes and diabetes with complications, hemiplegia and paraplegia, any malignancy including leukaemia and lymphoma, metastatic tumour, human immunodeficiency virus [HIV] infection and hypertension).

†adjusted for age, sex, charlson comorbidity index (myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, Renal failure, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes and diabetes with complications, hemiplegia and paraplegia, any malignancy including leukaemia and lymphoma, metastatic tumour, human immunodeficiency virus [HIV] infection and hypertension), NSAID, Colchicine, Prednisolone, PPI, Vitamin D, Bisphosphonates, Glucocorticoids, insulin, glucose, antihypertensives, nitrates, lipid, anticonvulsants, anticoagulants and DMARD.


Disclosure: P. H. Tsai, None; C. F. Kuo, None.

To cite this abstract in AMA style:

Tsai PH, Kuo CF. Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-of-stroke-among-patients-with-gout-in-taiwan-a-nationwide-population-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-stroke-among-patients-with-gout-in-taiwan-a-nationwide-population-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology